Published in Int J Cancer on December 20, 2004
Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer (2010) 1.76
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One (2013) 1.65
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther (2007) 1.38
DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer (2015) 1.25
Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem (2009) 1.12
Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res (2013) 1.03
Linking JNK Activity to the DNA Damage Response. Genes Cancer (2013) 0.89
Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines. Bioorg Med Chem Lett (2007) 0.87
A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells. Cell Death Dis (2013) 0.87
Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. J Biol Chem (2011) 0.87
Late activation of stress kinases (SAPK/JNK) by genotoxins requires the DNA repair proteins DNA-PKcs and CSB. Mol Biol Cell (2005) 0.84
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett (2005) 0.84
E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. Cancer Res (2014) 0.84
Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells. PLoS One (2013) 0.83
TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One (2012) 0.83
Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther (2016) 0.83
Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res (2014) 0.82
Involvement of Nrf2-mediated upregulation of heme oxygenase-1 in mollugin-induced growth inhibition and apoptosis in human oral cancer cells. Biomed Res Int (2013) 0.82
Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics (2009) 0.81
The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation. PLoS One (2013) 0.79
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget (2015) 0.79
Regulation of AKT gene expression by cisplatin. Oncol Lett (2013) 0.78
Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. Pediatr Blood Cancer (2013) 0.78
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Des Devel Ther (2009) 0.78
A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity. Curr Genomics (2016) 0.78
Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells. Biomed Res Int (2015) 0.77
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. Front Cell Dev Biol (2016) 0.75
ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. Neoplasia (2017) 0.75
The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy. Transl Oncol (2016) 0.75
DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) (2007) 4.04
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett (2012) 2.69
Mechanisms of human DNA repair: an update. Toxicology (2003) 2.24
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem (2006) 2.08
From traditional Chinese medicine to rational cancer therapy. Trends Mol Med (2007) 2.02
Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta (2010) 1.93
Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle (2010) 1.88
Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets (2006) 1.77
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol (2005) 1.73
Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy (2003) 1.71
Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer (2009) 1.56
Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis (2003) 1.54
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett (2006) 1.53
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A (2010) 1.48
How DNA lesions are turned into powerful killing structures: insights from UV-induced apoptosis. Mutat Res (2008) 1.43
Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol (2010) 1.41
Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med (2004) 1.37
Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol (2006) 1.36
Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res (2008) 1.31
Interprofessional Medication Management in Patients With Multiple Morbidities. Dtsch Arztebl Int (2016) 1.29
Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) (2008) 1.29
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One (2013) 1.24
Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res (2005) 1.23
The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol (2010) 1.23
Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther (2008) 1.22
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer (2010) 1.22
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer (2010) 1.21
Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res (2007) 1.21
Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci (2010) 1.20
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem (2007) 1.20
Proteasomal degradation of cytotoxic necrotizing factor 1-activated rac. Infect Immun (2002) 1.18
Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol (2005) 1.17
O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta (2011) 1.16
APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology (2003) 1.15
Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother Oncol (2009) 1.14
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol (2006) 1.14
P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg. PLoS One (2008) 1.14
Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. Proc Natl Acad Sci U S A (2011) 1.14
Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity. Nucleic Acids Res (2002) 1.14
Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J (2003) 1.11
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer (2010) 1.11
The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis (2010) 1.11
Combined antitumor effects of bee venom and cisplatin on human cervical and laryngeal carcinoma cells and their drug resistant sublines. J Appl Toxicol (2014) 1.11
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs (2005) 1.10
Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther (2011) 1.10
Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene (2002) 1.09
Molecular biology of cantharidin in cancer cells. Chin Med (2007) 1.08
MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer (2008) 1.08
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet (2011) 1.08
Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res (2007) 1.07
Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Curr Drug Metab (2011) 1.05
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol (2011) 1.05
Cell proliferation and DNA breaks are involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient Chinese hamster cells. Mol Biol Cell (2002) 1.03
Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res (2013) 1.03
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta (2012) 1.02
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. DNA Repair (Amst) (2010) 1.01
Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat Res (2009) 1.01
Influence of DNA repair on nonlinear dose-responses for mutation. Toxicol Sci (2013) 1.01
Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res (2007) 1.01
Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One (2011) 1.01
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs (2009) 1.00
Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol Appl Pharmacol (2008) 1.00
Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene (2004) 0.98
FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res (2009) 0.98
TraA and its N-terminal relaxase domain of the Gram-positive plasmid pIP501 show specific oriT binding and behave as dimers in solution. Biochem J (2005) 0.98
Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene (2005) 0.98
The cytotoxicity of RoekoSeal and AH plus compared during different setting periods. J Endod (2005) 0.97
Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem (2012) 0.96
Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res (2006) 0.96
Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB. J Biol Chem (2004) 0.96
Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett (2005) 0.95
Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry (2007) 0.95
From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer (2003) 0.94
Myricetin-mediated lifespan extension in Caenorhabditis elegans is modulated by DAF-16. Int J Mol Sci (2013) 0.94
Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem (2006) 0.93
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther (2004) 0.93
A role for UV-light-induced c-Fos: Stimulation of nucleotide excision repair and protection against sustained JNK activation and apoptosis. Carcinogenesis (2006) 0.93
Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res (2005) 0.93
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet (2010) 0.92
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol (2006) 0.92
Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. EMBO Mol Med (2013) 0.92
c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF. Nucleic Acids Res (2006) 0.92